Senate Democrats Push Drug Pricing, Tax, Climate Package

Sen. Joe Manchin (D-W. Va.) on Wednesday said he had signed off on a revised “Build Back Better” plan, renamed the “Inflation Reduction Act of 2022,” which includes sweeping drug price controls along with tax increases and billions for climate and energy spending. The bill’s drug pricing provisions would allow Medicare to negotiate drug prices […]

Read More

ARUP’s New Monkeypox Test Can Be Performed on More Specimen Types on High-Throughput Instruments

SALT LAKE CITY, July 25, 2022 — ARUP Laboratories today announced that it has begun in-house testing for monkeypox. The Orthopoxvirus (includes monkeypox virus) by PCR test (test code 3005716) is a real-time polymerase chain reaction (RT-PCR) test to detect the DNA of orthopoxviruses, including monkeypox. ARUP’s test is similar to the CDC assay that […]

Read More

BD Completes Acquisition of Parata Systems

BD (Becton, Dickinson and Company) (NYSE: BDX) today announced it has completed the acquisition of Parata Systems. Parata advances BD’s transformative solutions strategy by providing a portfolio of innovative pharmacy automation solutions that power a growing network of pharmacies to reduce costs, enhance patient safety and improve the patient experience for retail, hospital and long-term care […]

Read More

BioUtah Joins State BIOs in Opposing Drug Price Controls

Senate Democrats are inching closer to a vote on a revived “Build Back Better” package, largely focused on drug pricing. The package would give Medicare the authority to negotiate drug prices and impose inflation rebates. The negotiation process, in practice, would function more like government price controls since drug manufacturers deemed non-compliant with the requirements […]

Read More